WAT stock forecast, quote, news & analysis
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools... Show more
Waters Corporation (WAT) Stock Analysis: A Transformative Diagnostics Deal Reshapes the Growth Story
Key Takeaways
- Waters Corporation (WAT) shares advanced roughly 5% over the trailing 30 days, moving from about $439 in late September to about $463 by the end of October.
- The 30-day move was modest and below the 10% threshold, reflecting a steady consolidation and uptrend rather than a sharp, catalyst-driven swing.
- Waters' growth profile is being reshaped by its acquisition of a biosciences and diagnostic solutions business, which closed in February 2026 and substantially expanded reported revenue.
- Second-quarter results, reported in early August, beat consensus on both revenue and adjusted earnings per share, and management raised its full-year guidance.
- Demand tied to GLP-1 testing grew more than 40% in the most recent reported quarter, underscoring a key growth driver for the company.
- For additional detail on valuation and expectations, explore Waters' Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to discover AI-driven trading strategies active across thousands of tickers.
Current Market Snapshot
Waters Corporation shares closed near $463 at the end of October, a gain of about 5.3% from the roughly $439 level recorded 30 days earlier. The advance unfolded gradually, with the stock briefly trading above $480 before a pullback in the final session of the period trimmed some of the gains. As a large-capitalization name in the life sciences tools and diagnostics space, Waters has drawn renewed investor attention following a second-quarter earnings beat and an upward revision to its full-year outlook, even as acquisition-related accounting charges have weighed on reported net income.
Waters Corporation (WAT) Business Overview and Competitive Position
Waters Corporation is a global provider of analytical instruments, consumables, software, and services used across pharmaceutical, life science, biochemical, industrial, food, and environmental applications. Its core franchises include high-performance liquid chromatography (HPLC and UPLC) and mass spectrometry systems, complemented by thermal analysis instruments and a recurring stream of consumables and service revenue that supports a razor-and-blade business model.
The company has historically competed alongside other major analytical instrumentation providers, differentiated by a large installed base, deep scientific expertise, and a strong presence in regulated, high-volume testing environments. Its recent expansion into biosciences and diagnostics has broadened the addressable market and added scale to the top line, positioning Waters as a more diversified player in life sciences testing while retaining its leadership in separation science and mass spectrometry.
Recent Developments Driving WAT
The most significant development shaping Waters' recent trajectory is its acquisition of a biosciences and diagnostic solutions business, which closed on February 9, 2026. The transaction materially expanded reported revenue and moved the company more deeply into diagnostics, though purchase-accounting adjustments contributed to reported net losses in the first and second quarters of 2026 even as adjusted results improved.
Second-quarter results, reported in early August, provided a key catalyst. Reported revenue of about $1.65 billion exceeded consensus estimates of roughly $1.62 billion, and adjusted earnings per share of $3.05 topped expectations of approximately $3.01. Organic revenue rose 7% as reported and 9% in constant currency, and management highlighted robust demand across pharmaceutical, academic, and government markets. GLP-1 testing revenue grew more than 40% during the quarter. In response, the company raised its full-year organic constant-currency revenue growth outlook to a range of 7% to 9% and its adjusted EPS guidance to $14.45 to $14.65.
Analyst commentary following the report was generally constructive, with questions focused on the sustainability of growth in the acquired businesses, pricing initiatives, a China-focused turnaround effort, and the integration of newly launched products. These factors, combined with broad sector strength in life sciences tools, supported the stock's modest upward drift over the period.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a platform that operates hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a focused view of strategies that are currently standing out. The featured bots vary widely in approach, holding timeframe, and performance metrics, so users can compare different styles of automated trading. For those interested in supplementing their research with algorithmic insights, exploring the current lineup can offer an additional perspective on market activity.
2026 Outlook and What Investors Should Watch
Looking ahead, investors are likely to focus on the company's third-quarter results, which were expected around early November, along with the integration trajectory of the acquired biosciences and diagnostics business. For the third quarter, management guided to organic reported revenue of $850 million to $867 million and adjusted EPS of $3.95 to $4.05, implying meaningful year-over-year growth. Full-year targets call for organic constant-currency revenue growth of 7% to 9% and adjusted EPS of $14.45 to $14.65.
Key factors to monitor include continued momentum in GLP-1-related testing, execution on pricing and cost-synergy initiatives, progress on the China turnaround, and the impact of foreign-exchange headwinds on reported results. Acquisition-related purchase accounting is expected to keep pressure on GAAP profitability in the near term, so investors may weigh adjusted metrics against reported figures. As with any equity, macroeconomic conditions and demand cycles in pharmaceutical and diagnostics end markets remain important variables.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
WAT in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 27, 2026
WAT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 25 of the 38 cases the stock fell afterwards. This puts the odds of success at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for WAT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 21 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 70 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on WAT as a result. In 60 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for WAT just turned positive on October 21, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
Following a +2.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 179 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 118 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.907) is normal, around the industry mean (65.876). WAT has a moderately high P/E Ratio (112.947) as compared to the industry average of (3.542). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis
Industry MedicalSpecialties